Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improve-AS: Ivarmacitinib for active ankylosing spondylitis (prospective multicenter real-world study)
ChiCTR2600118422Phase 4Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivarmacitinib in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA), sponsored by Shanghai Changzheng Hospital. Primary endpoint: ASAS40 response. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on ChiCTR2600118422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118422.